Study data

PDO 2.0 tumor–immune response

Two PDO 2.0 studies in ccRCC and NSCLC show how tissue context, immune baseline and treatment-related readouts inform follow-on sample, stimulation and assay plans.

Request the full white paper View study evidence ↘

Model & sampleccRCC and NSCLC PDO 2.0 study models

Study setupIL-2 and immune-checkpoint study conditions

AssaysccRCC: PanCK, CD3, PD-L1, CD8, CD56 and apoptosis/necrosis flow; NSCLC: CD4/CD8 counts within CD3-positive TILs.

STUDY AND RESULTS

From baseline context to immune response and treatment-related cell-death readouts

Tissue baseline, immune stimulation and treatment-response readouts offer complementary views for tumor–immune studies.

01Tissue and model context

Compare tumor-epithelial and sample-associated immune signals

Source tissue and PDOs at days 7 and 28 show PanCK, CD3 and DAPI signals side by side for comparison of tumor-epithelial and sample-associated immune signals.

Provides baseline data for immune quantification and treatment studies

02Stimulation response

Test the response to immune stimulation

Tissue imaging under ±IL-2 conditions shows the response to stimulation and can be combined with subsequent flow and cytokine assays.

Informs dose, time-point and cytokine-endpoint selection

03Treatment response

Connect immune-cell changes with cell-death readouts

PD-L1-, CD8- and CD56-associated flow profiles are interpreted alongside early-apoptosis and necrosis readouts to compare immune-associated and cell-death changes under ICB conditions.

Informs candidate and independent-sample comparisons

View the complete study figure set

ccRCC tissue and PDO culture characterization, IL-2 stimulation and ICB-related flow readouts in PDO 2.0 — The complete figure set for tissue and culture context, IL-2 stimulation and ICB-related flow readouts.

IMAGING & FLOW ASSAYS

Use imaging and flow results to select the model, treatment conditions and assays

Study stageMeasured endpointsHow results inform your programStudy extensions

01Source tissue + PDO d7/d28

PanCK, CD3, DAPI and tissue morphology

Measurable tumor context and immune signals

Multi-field quantification, replication and sample-specific windows

02±IL-2 conditions

CD3, PanCK and DAPI immunofluorescence

Interpretable change after immune stimulation

Dose/time, cytokine and gating analyses

03Control + ICB conditions

PD-L1-, CD8- and CD56-associated flow profiles with apoptosis and necrosis

Relationship between immune change and cell-death readouts

Candidate mechanism, target context and independent-sample comparisons

WHAT THE DATA ENABLE

Plan candidate and dose comparisons and confirmation in independent samples

Use immune-cell profiles and treatment responses to design the next candidate, dose and independent-sample study.

HOW THE STUDY IS BUILT

Compare immune and cell-death changes across treatment conditions

Sample baseline informs the culture window, flow-cytometry gating and replication design so immune and cell-death-related changes can be compared clearly across treatment conditions.

EXTEND THE STUDY

Build the study around the candidate mechanism

Immuno-oncology studies

Combine baseline immune profiling, treatment conditions and cell-death readouts in one study.

↗

Antibody, multispecific and TCE

Select the model and assays around target, effector cells and killing endpoints.

↗

Mechanism and biomarkers

Add mechanistic endpoints and confirmatory studies for priority response signals.

↗

Related models and services

Choose the right models and services for the next study

DOCUMENT REQUEST

Request the full white paper on PDO 2.0 / ALI

Share your name, organization and work contact details, with your research area if useful. After reviewing the request, our team will contact you to confirm the delivery method and arrange the full white paper.

Request the full white paper See how we work ↗